JaeHongParkMD

PubMed

• Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
  Ryan N Ptashkin, Mark D Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S Bowman, JinJuan Yao, Jacklyn Casanova, Yun-Te David Lin, Kseniya Petrova-Drus, Abhinita S Moh...> ;Nature Communications. 2023 Oct 28
• 6 citations
  Cooperative CAR targeting to selectively eliminate AML and minimize escape.
  Sascha Haubner, Jorge Mansilla-Soto, Sarah Nataraj, Friederike Kogel, Qing Chang, Elisa de Stanchina, Michael Lopez, Mei Rosa Ng, Kathryn Fraser, Marion Subklewe, Jae ...> ;Cancer Cell. 2023 Nov 13
• 1 citations
  Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia.
  Devlin, S., von Keudell, G., Vemuri, S., Shukla, M., Falco, V., Cuello, B., Park, J., Durham, B., Winer, E., Huntington, S., Gore, S., Stone, R., Abdel-Wahab, O., Tall...> ;NEJM Evidence. 2023 Oct 1
• Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
  Karthik Nath, Jasme Lee, Theresa A Elko, Lauren Levy, Elaina Preston, Sean M Devlin, Doris M Ponce, Richard J Lin, Brian C Shaffer, Christina Cho, Ioannis Politikos, A...> ;American Journal of Hematology. 2023 Dec 1
• 2 citations
  Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with bre...
  Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzac...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
• 1 citations
  Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review.
  Franco Locatelli, Bijal Shah, Tracy Thomas, Kelly Velasco, Babatunde Adedokun, Ibrahim Aldoss, Lia Gore, Dieter Hoelzer, Renato Bassan, Jae H Park, Nicolas Boissel, Ha...> ;Leukemia & Lymphoma. 2023 Oct 1
• 4 citations
  Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma.
  Richard J Lin, Soo Jung Kim, Samantha Brown, Theresa A Elko, Josel D Ruiz, Danielle M Hanley, M Lia Palomba, Miguel-Angel Perales, Gunjan L Shah, Parastoo B Dahi, Mich...> ;Blood Advances. 2023 Jul 25
• 12 citations
  CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
  Jae H Park, Karthik Nath, Sean M Devlin, Craig S Sauter, M Lia Palomba, Gunjan Shah, Parastoo Dahi, Richard J Lin, Michael Scordo, Miguel-Angel Perales, Roni Shouval, ...> ;Nature Medicine. 2023 Jul 1
• Validation of a High-Sensitivity Assay for Detection of Chimeric Antigen Receptor T-Cell Vectors Using Low-Partition Digital PCR Technology.
  Maria E Arcila, Utsav Patel, Amir Momeni-Boroujeni, JinJuan Yao, Roger Chan, Joe Chan, Ivelise Rijo, Wayne Yu, Nelio Chaves, Hina Patel, Srushti Kakadiya, Sean Lachhan...> ;The Journal of Molecular Diagnostics. 2023 Sep 1
• 7 citations
  Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
  Syed S Mahmood, Peter A Riedell, Stephanie Feldman, Gina George, Stephen A Sansoterra, Thomas Althaus, Mahin Rehman, Elena Mead, Jennifer E Liu, Richard B Devereux, Jo...> ;European Heart Journal. 2023 Jun 9
• 3 citations
  Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.
  Mark B Geyer, Brian C Shaffer, Bhavana Bhatnagar, Alice S Mims, Victoria Klein, Deepika Dilip, Jacob L Glass, Gerard Lozanski, Hani Hassoun, Heather Landau, Yanming Zh...> ;Blood Advances. 2023 Jul 11
• 3 citations
  Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
  Ibrahim Aldoss, Bijal D Shah, Jae H Park, Lori Muffly, Aaron C Logan, Patrick Brown, Wendy Stock, Elias J Jabbour> ;American Journal of Hematology. 2023 Apr 1
• 8 citations
  Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
  Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, Justin Taylor, Eileen Boyle, Juan Arango Ossa, Jacob Jahn, Maurizio Affer, Tulasigeri M Totiger, David Coffey, ...> ;Blood. 2023 May 11
• 10 citations
  Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
  Harper Hubbeling, Emily A Silverman, Laure Michaud, Ana Alarcon Tomas, Roni Shouval, Jessica Flynn, Sean Devlin, N Ari Wijetunga, Kathryn R Tringale, Connie Batlevi, P...> ;Transplantation and Cellular Therapy. 2023 Apr 1
• 2 citations
  Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained ...
  Kenneth Cornetta, Jing Yao, Kimberley House, Lisa Duffy, Prasad S Adusumilli, Rachel Beyer, Claire Booth, Malcolm Brenner, Kevin Curran, Bambi Grilley, Helen Heslop, C...> ;Molecular Therapy. 2023 Mar 1
• 3 citations
  Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.
  Farhad Ravandi, Robert J Kreitman, Enrico Tiacci, Leslie Andritsos, Versha Banerji, Jacqueline C Barrientos, Seema A Bhat, James S Blachly, Alessandro Broccoli, Timoth...> ;Blood Cancer Journal. 2022 Dec 13
• 17 citations
  Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an ...
  Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Ryan D Cassaday, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzachanis, Kr...> ;Journal of Hematology & Oncology. 2022 Dec 10
• 8 citations
  Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.
  Anjali S Advani, Anna Moseley, Kristen M O'Dwyer, Brent L Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L Atallah, Aaron T Gerds, Susan M O...> ;Blood Advances. 2023 Apr 11
• 83 citations
  GPRC5D-Targeted CAR T Cells for Myeloma.
  Sham Mailankody, Sean M Devlin, Jonathan Landa, Karthik Nath, Claudia Diamonte, Elizabeth J Carstens, Douglas Russo, Romany Auclair, Lisa Fitzgerald, Briana Cadzin, Xi...> ;The New England Journal of Medicine. 2022 Sep 29
• 19 citations
  Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
  Meghan C Thompson, Rosemary A Harrup, Catherine C Coombs, Lindsey E Roeker, Jeffrey J Pu, Michael Y Choi, Paul M Barr, John N Allan, Martin Šimkovič, Lori Leslie, Joan...> ;Blood Advances. 2022 Aug 9
• 21 citations
  The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
  Armin Ghobadi, Michael Slade, Hagop Kantarjian, Julio Alvarenga, Ibrahim Aldoss, Kahee A Mohammed, Elias Jabbour, Rawan Faramand, Bijal Shah, Frederick Locke, Warren F...> ;Blood. 2022 Nov 17
• 2 citations
  Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
  Lindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey, Andrew D Zelenetz, Lorenzo Falchi, Jae H Park, David J Straus, Cami...> ;Clinical Cancer Research. 2022 Sep 15
• 4 citations
  Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.
  Zachary D Epstein-Peterson, Andriy Derkach, Susan Geyer, Krzysztof Mrózek, Jessica Kohlschmidt, Jae H Park, Sridevi Rajeeve, Eytan M Stein, Yanming Zhang, Harry Iland,...> ;Blood Advances. 2022 Jun 14
• 60 citations
  Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
  Robert Stuver, Gunjan L Shah, Neha S Korde, Lindsey E Roeker, Anthony R Mato, Connie L Batlevi, David J Chung, Sital Doddi, Lorenzo Falchi, Boglarka Gyurkocza, Audrey ...> ;Cancer Cell. 2022 Jun 13
• 56 citations
  Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.
  Fanying Tang, Duo Xu, Shangqian Wang, Chen Khuan Wong, Alexander Martinez-Fundichely, Cindy J Lee, Sandra Cohen, Jane Park, Corinne E Hill, Kenneth Eng, Rohan Bareja, ...> ;Science. 2022 May 27
• Join now to see all

Abstracts/Posters

• Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Th...
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia
  Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• CAR-T Cell Therapy and Stem Cells in Acute Lymphoblastic Leukemia 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all